Get a quote

In Silico and PBPK Modelling

Working with your full project team, Sygnature Discovery’s experience in Silico modelling and PBPK Modelling and simulation team guides you throughout the lifetime of your project, helping to:

  • define early discovery screening cascades, interpret in vitro data and recommend options for progression to in vivo studies.
  • make recommendations of dose and dosing regimen for pharmacodynamic (PD) studies through PK and PK/PD modelling and simulation.
  • predict human PK using allometric and PBPK modelling approaches.
  • predict efficacious pharmacological dose (integrate PK prediction with PK/PD hypothesis).
  • assess drug-drug interaction risks [metabolising enzymes (CYPs, UGTs, non-hepatic) and transporters].
  • due diligence (in-licensing evaluation or out-licensing support).

In Silico Modelling and PBPK modelling – Gold standard modelling

Sygnature uses the GastroPlusTM software package that simulates absorption, distribution, metabolism and elimination in humans and animals from a range of dose routes including oral, intravenous, inhaled, ocular and dermal. This enables data integration within the context of a virtual animal or human model. Having this in silico modelling understanding can help us make faster and more informed development decisions. It has been identified as the number one commercially ranked program for in vitro-in vivo extrapolation and has been the focus of several publications from the FDA.

Latest News

View All

First patients dosed in Phase 1a clinical…

Sygnature Discovery Appoints Industry Leaders To Board…

Sygnature Discovery invests £3.75M in Compound Management…

Sygnature Discovery collaborates with Axol Bioscience to…